EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Brilacidin, a novel antifungal agent against Cryptococcus neoformans

Camila Diehl iD, Camila Figueiredo Pinzan, Patrícia Alves de Castro, Endrews Delbaje, Laura C García Carnero, Eddy Sánchez-León, Kabir Bhalla, James W Kronstad iD, Dong-Gyu Kim, Tamara L Doering iD, Sondus Alkhazraji, Nagendra N Mishra iD und 8 weitere

mBio · 2024

DOI: 10.1128/mbio.01031-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mBio, 2024. Verfasst von Camila Diehl und 19 weiteren Autor:innen. Beteiligte Einrichtung: Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, Brazil. Hauptthemen laut MEDLINE: Antifungal Agents, Cryptococcus neoformans, Cryptococcosis, Saccharomyces cerevisiae. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cryptococcus neoformans causes cryptococcosis, one of the most prevalent fungal diseases, generally characterized by meningitis. There is a limited and not very effective number of drugs available to combat this disease. In this manuscript, we show the host defense peptide mimetic brilacidin (BRI) as a promising antifungal drug against C. neoformans . BRI can affect the organization of the cell membrane, increasing the fungal cell permeability. We also investigated the effects of BRI against the model system Saccharomyces cerevisiae by analyzing libraries of mutants grown in the presence of BRI. In S. cerevisiae , BRI also affects the cell membrane organization, but in addition the cell wall integrity pathway and calcium metabolism. In vivo experiments show BRI significantly reduces C. neoformans survival inside macrophages and partially clears C. neoformans lung infection in an immunocompetent murine model of invasive pulmonary cryptococcosis. We also observed that BRI interacts with caspofungin (CAS) and amphotericin (AmB), potentiating their mechanism of action against C. neoformans . BRI + CAS affects endocytic movement, calcineurin, and mitogen-activated protein kinases. Our results indicate that BRI is a novel antifungal drug against cryptococcosis. IMPORTANCE Invasive fungal infections have a high mortality rate causing more deaths annually than tuberculosis or malaria. Cryptococcosis, one of the most prevalent fungal diseases, is generally characterized by meningitis and is mainly caused by two closely related species of basidiomycetous yeasts, Cryptococcus neoformans and Cryptococcus gattii . There are few therapeutic options for treating cryptococcosis, and searching for new antifungal agents against this disease is very important. Here, we present brilacidin (BRI) as a potential antifungal agent against C. neoformans . BRI is a small molecule host defense peptide mimetic that has previously exhibited broad-spectrum immunomodulatory/anti-inflammatory activity against bacteria and viruses. BRI alone was shown to inhibit the growth of C. neoformans , acting as a fungicidal drug, but surprisingly also potentiated the activity of caspofungin (CAS) against this species. We investigated the mechanism of action of BRI and BRI + CAS against C. neoformans . We propose BRI as a new antifungal agent against cryptococcosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsCryptococcus neoformansCryptococcosisSaccharomyces cerevisiaeAnimalsMiceDisease Models, AnimalMacrophagesMicrobial Sensitivity TestsCaspofunginFemaleCell MembraneAmphotericin B

Stichwörter der Autor:innen

Cryptococcus neoformansantifungal agentbrilacidincaspofungin

Substanzen

Antifungal AgentsCaspofunginAmphotericin B

Autor:innen und Institutionen

  • Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, Brazil.
  • Michael Smith Laboratories, University of British Columbia, Vancouver, British Columbia, Canada.
  • Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Division of Infectious Diseases, The Lundquist Institute for Biomedical Innovation at Harbor-University of California Los Angeles (UCLA) Medical Center, Torrance, California, USA.
  • David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
  • RIKEN Center for Sustainable Resource Science, Wako, Saitama, Japan.

ORCID-Profile: Camila Diehl, James W Kronstad, Tamara L Doering, Nagendra N Mishra, Gustavo H Goldman

Förderung

  • NIAID NIH HHS
  • Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Zitieren

APA

Diehl, C., Pinzan, C. F., de Castro, P. A., Delbaje, E., García Carnero, L. C., Sánchez-León, E., Bhalla, K., Kronstad, J. W., Kim, D., Doering, T. L., Alkhazraji, S., Mishra, N. N., Ibrahim, A. S., Yoshimura, M., Vega Isuhuaylas, L. A., Pham, L. T. K., Yashiroda, Y., Boone, C., Dos Reis, T. F., & Goldman, G. H. (2024). Brilacidin, a novel antifungal agent against Cryptococcus neoformans. mBio. https://doi.org/10.1128/mbio.01031-24

Vancouver

Diehl C, Pinzan CF, de Castro PA, Delbaje E, García Carnero LC, Sánchez-León E, et al. Brilacidin, a novel antifungal agent against Cryptococcus neoformans. mBio. 2024. doi:10.1128/mbio.01031-24

BibTeX
@article{Diehl2024,
  author = {Diehl, Camila and Pinzan, Camila Figueiredo and de Castro, Patrícia Alves and Delbaje, Endrews and García Carnero, Laura C and Sánchez-León, Eddy and Bhalla, Kabir and Kronstad, James W and Kim, Dong-Gyu and Doering, Tamara L and Alkhazraji, Sondus and Mishra, Nagendra N and Ibrahim, Ashraf S and Yoshimura, Mami and Vega Isuhuaylas, Luis Alberto and Pham, Lien Thi Kim and Yashiroda, Yoko and Boone, Charles and Dos Reis, Thaila Fernanda and Goldman, Gustavo H},
  title = {Brilacidin, a novel antifungal agent against Cryptococcus neoformans},
  journal = {mBio},
  year = {2024},
  doi = {10.1128/mbio.01031-24}
}
Kostenlos starten →